Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BIIB033 (Opicinumab) Manufacturing Processes in Healthy Volunteers
NCT02833142Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicinumab in multiple sclerosis (MS) and optic neuritis (ON) (2 arms), sponsored by Biogen. Primary endpoints: Area under the concentration-time curve from time 0 to infinity, Area under the concentration-time curve from time 0 to Day 85 and 1 more. Started Jul 2016; status: completed.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)optic neuritis (ON)
Beyond the preview
Go deeper on NCT02833142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833142.